{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "7701051", "DateCompleted": {"Year": "1995", "Month": "04", "Day": "28"}, "DateRevised": {"Year": "2019", "Month": "07", "Day": "26"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0033-3158", "JournalIssue": {"Volume": "116", "Issue": "4", "PubDate": {"Year": "1994", "Month": "Dec"}}, "Title": "Psychopharmacology", "ISOAbbreviation": "Psychopharmacology (Berl)"}, "ArticleTitle": "Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain.", "Pagination": {"StartPage": "469", "EndPage": "474", "MedlinePgn": "469-74"}, "Abstract": {"AbstractText": ["Regional differences in the modulation of [3H] muscimol binding to GABAA receptor complexes by kavapyrones, compounds of the rhizome of the plant Piper methysticum which possess sedative activity, were demonstrated using membrane fractions obtained from target brain centers of kavapyrone action: hippocampus (HIP), amygdala (AMY) and medulla oblongata (MED), and from brain centers outside the main kavapyrone effects as frontal cortex (FC) and cerebellum (CER). The kava extract enhanced the binding of [3H] muscimol in a concentration-dependent manner with maximal potentiation of 358% over control in HIP followed by AMY and MED (main target brain centers). Minimal stimulation was observed in CER followed by FC. In contrast, apart from CER, the potency of kavapyrones was similar in the brain areas investigated with EC50 values ranging between 200 and 300 microM kavapyrones. Scatchard analysis revealed that the observed effects of kavapyrones were due to an increase in the number of binding sites (Bmax), rather than to a change in affinity. At a kavapyrone concentration of 500 microM the order of enhancement in Bmax was HIP = AMY > MED > FC > CER. When kavapyrones are included together with pentobarbital or HPO the two classes of compounds produced a more than additive, i.e., synergetic effect on [3H] muscimol binding. Our findings suggest that one way kavapyrones might mediate sedative effects in vivo is through effects on GABAA receptor binding."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institut f\u00fcr Physiologische Chemie, Universit\u00e4tsklinikum Essen, Germany."}], "LastName": "Jussofie", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Schmiz", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Hiemke", "ForeName": "C", "Initials": "C"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Psychopharmacology (Berl)", "NlmUniqueID": "7608025", "ISSNLinking": "0033-3158"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrones"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, GABA"}, {"RegistryNumber": "0", "NameOfSubstance": "Steroids"}, {"RegistryNumber": "2763-96-4", "NameOfSubstance": "Muscimol"}, {"RegistryNumber": "I4744080IR", "NameOfSubstance": "Pentobarbital"}, {"RegistryNumber": "Q3JTX2Q7TU", "NameOfSubstance": "Diazepam"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Binding, Competitive"}, {"QualifierName": ["drug effects"], "DescriptorName": "Brain Chemistry"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Diazepam"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": ["pharmacokinetics"], "DescriptorName": "Muscimol"}, {"QualifierName": [], "DescriptorName": "Ovariectomy"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Pentobarbital"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["pharmacokinetics", "pharmacology"], "DescriptorName": "Pyrones"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Receptors, GABA"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Steroids"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "FASEB J. 1990 Mar;4(5):1469-80", "ArticleIdList": ["2155149"]}, {"Citation": "J Pharm Sci. 1988 Dec;77(12):1003-6", "ArticleIdList": ["3244102"]}, {"Citation": "Br J Pharmacol. 1988 Aug;94(4):1257-69", "ArticleIdList": ["2850060"]}, {"Citation": "J Neurosci. 1992 Mar;12(3):1063-76", "ArticleIdList": ["1312132"]}, {"Citation": "Neuropharmacology. 1987 Jul;26(7B):923-30", "ArticleIdList": ["2821435"]}, {"Citation": "J Pharmacol Exp Ther. 1993 Feb;264(2):638-47", "ArticleIdList": ["8382279"]}, {"Citation": "Mol Neurobiol. 1989 Winter;3(4):275-304", "ArticleIdList": ["2560920"]}, {"Citation": "J Pharmacol Exp Ther. 1992 Aug;262(2):801-8", "ArticleIdList": ["1323664"]}, {"Citation": "Xenobiotica. 1979 Jan;9(1):1-16", "ArticleIdList": ["760318"]}, {"Citation": "Int Rev Neurobiol. 1985;27:1-61", "ArticleIdList": ["3910602"]}, {"Citation": "Eur J Pharmacol. 1992 May 14;215(2-3):265-9", "ArticleIdList": ["1396990"]}, {"Citation": "Mol Pharmacol. 1987 Aug;32(1):266-77", "ArticleIdList": ["3039341"]}, {"Citation": "Acta Endocrinol (Copenh). 1993 Nov;129(5):480-5", "ArticleIdList": ["8279228"]}, {"Citation": "J Neurosci. 1982 Dec;2(12):1812-23", "ArticleIdList": ["6292381"]}, {"Citation": "Biol Chem Hoppe Seyler. 1993 Apr;374(4):265-70", "ArticleIdList": ["8101089"]}, {"Citation": "Pharmacol Toxicol. 1992 Aug;71(2):120-6", "ArticleIdList": ["1332016"]}, {"Citation": "Proc Natl Acad Sci U S A. 1981 Nov;78(11):7180-4", "ArticleIdList": ["6273918"]}, {"Citation": "Life Sci. 1991;49(3):207-16", "ArticleIdList": ["1648158"]}, {"Citation": "Arch Int Pharmacodyn Ther. 1962 Aug 1;138:505-36", "ArticleIdList": ["13935274"]}, {"Citation": "Trends Pharmacol Sci. 1992 Dec;13(12):446-50", "ArticleIdList": ["1338138"]}, {"Citation": "Biol Chem Hoppe Seyler. 1993 Jan;374(1):61-8", "ArticleIdList": ["8382494"]}, {"Citation": "Prog Neurobiol. 1992;38(4):379-95", "ArticleIdList": ["1349441"]}, {"Citation": "J Med Pharm Chem. 1959 Feb;1(1):95-103", "ArticleIdList": ["13655031"]}, {"Citation": "Biochem Pharmacol. 1992 Jul 7;44(1):11-5", "ArticleIdList": ["1321625"]}, {"Citation": "J Pharmacol Exp Ther. 1991 Mar;256(3):1154-60", "ArticleIdList": ["1848629"]}], "ReferenceList": []}], "History": [{"Year": "1994", "Month": "12", "Day": "1"}, {"Year": "1994", "Month": "12", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1994", "Month": "12", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["7701051", "10.1007/BF02247480"]}}]}